New meets old: A case study and review of novel therapeutics for the treatment of CLL in older patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 10, 2014, Pages 1371-1375

  Gupta, Neel K ^a   Andreadis, Charalambos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; METHYLPREDNISOLONE; OBINUTUZUMAB; PROTEIN P53; RITUXIMAB; VENETOCLAX; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; THALIDOMIDE;

ADD ON THERAPY; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CASE REPORT; CASE STUDY; CERVICAL LYMPHADENOPATHY; CHARLSON COMORBIDITY INDEX; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CUMULATIVE ILLNESS RATING SCALE; CYTOGENETICS; DISEASE COURSE; DRUG WITHDRAWAL; FATIGUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; LYMPHOCYTE COUNT; MALE; MEASLES LIKE RASH; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84908667505     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0135     Document Type: Review

References (25)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2008/results-merged/topic-med-age.pdf. Accessed September 11, 2014.
3. Zelenetz AD, Gordon LI, Wierda WG, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 4.2014. Available at: NCCN.org. Accessed September 4, 2014.
4. Klabunde CN, Legler JM, Warren JL, et al. A refned comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584-590.
5. Charlson M, Szatrowski T P, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251.
6. Parmelee PA, Thuras PD, Katz IR, et al. Validation of the cumulative illness rating-scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-137.
7. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.
8. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lypmhoma 2009;50:171-178.
9. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014;99:1095-1100.
10. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fudarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
11. Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013;31:440-447.
12. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fudarabine compared with chlorambucil does not result in major beneft for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-3391.
13. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fudarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:1947-1950.
14. Lozanski G, Heerema NA, Flinn I W, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281.
15. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-2417.
16. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-1110.
17. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fudarabine (F), cyclophosphamide (C), and rituximab (R) versus fudarabine and cyclophosphamide (FC) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Presented at the ASH 50th Annual Meeting; December 6-9, 2008; San Francisco, CA. Abstract 325.
18. FDA approves Gazyva for chronic lymphocytic leukemia. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm373209.htm. Accessed September 4, 2014.
19. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
20. Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients [abstract]. Presented at the ASH 55th Annual Meeting; December 7-10, 2013; New Orleans, LA. Abstract 675.
21. Farooqui M, Aue G, Valdez J, et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p [abstract]. Presented at the ASH 55th Annual Meeting; December 7-10, 2013; New Orleans, LA. Abstract 673
22. Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [abstract]. Presented at the ASH 55th Annual Meeting; December 7-10, 2013; New Orleans, LA. Abstract 872.
23. Furman RR, Sharman J P, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.
24. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 2.2013. To view the most recent version of these guidelines, visit NCCN.org.
25. FDA Statement: FDA halts clinical trial of drug Revlimid (lenalidomide) for chronic lymphocytic leukemia due to safety concerns. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm361444.htm. Accessed September 4, 2014.